-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200 Day Moving Average of $1.07
VBI Vaccines (NASDAQ:VBIV) Shares Pass Below 200 Day Moving Average of $1.07
Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as low as $0.70. VBI Vaccines shares last traded at $0.71, with a volume of 389,743 shares.
Analysts Set New Price Targets
Separately, Raymond James decreased their price target on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
Get VBI Vaccines alerts:VBI Vaccines Trading Down 3.2 %
The company has a market capitalization of $182.28 million, a P/E ratio of -1.81 and a beta of 1.86. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.29 and a quick ratio of 2.19. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.07.
VBI Vaccines (NASDAQ:VBIV – Get Rating) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.11). The business had revenue of $0.35 million during the quarter, compared to analysts' expectations of $0.70 million. VBI Vaccines had a negative return on equity of 75.37% and a negative net margin of 15,391.36%. As a group, equities research analysts anticipate that VBI Vaccines Inc. will post -0.37 earnings per share for the current year.Institutional Investors Weigh In On VBI Vaccines
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. State Street Corp grew its holdings in VBI Vaccines by 31.1% in the first quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after purchasing an additional 3,844,698 shares during the period. Millennium Management LLC grew its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after purchasing an additional 1,209,393 shares during the period. Renaissance Technologies LLC grew its holdings in shares of VBI Vaccines by 358.7% during the second quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 617,400 shares during the last quarter. Frontier Wealth Management LLC grew its holdings in shares of VBI Vaccines by 1,571.7% during the first quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock valued at $951,000 after buying an additional 565,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of VBI Vaccines by 88.9% during the first quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 380,839 shares during the last quarter. Hedge funds and other institutional investors own 39.96% of the company's stock.
About VBI Vaccines
(Get Rating)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
Featured Stories
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of VBI Vaccines Inc. (NASDAQ:VBIV – Get Rating) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.07 and traded as low as $0.70. VBI Vaccines shares last traded at $0.71, with a volume of 389,743 shares.
VBI疫苗公司(纳斯达克代码：VBIV-GET评级)的股价在周五的交易中跌破200日移动均线。该股的200日移动均线切入位为1.07美元，交易价格低至0.70美元。VBI疫苗公司的股票最新报0.71美元，成交量为389,743股。
Analysts Set New Price Targets
分析师设定新的价格目标
Separately, Raymond James decreased their price target on shares of VBI Vaccines from $6.00 to $5.00 and set a "strong-buy" rating for the company in a research note on Tuesday, August 9th.
另外，雷蒙德·詹姆斯将VBI疫苗的目标股价从6.00美元下调至5.00美元，并在8月9日(星期二)的一份研究报告中为该公司设定了“强力买入”评级。
VBI Vaccines Trading Down 3.2 %
VBI疫苗价格下跌3.2%
The company has a market capitalization of $182.28 million, a P/E ratio of -1.81 and a beta of 1.86. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.29 and a quick ratio of 2.19. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.07.
该公司市值为1.8228亿美元，市盈率为-1.81，贝塔系数为1.86。该公司的债务权益比为0.20，流动比率为2.29，速动比率为2.19。该股的50日移动均线切入位在0.91美元，200日移动均线切入位在1.07美元。
Institutional Investors Weigh In On VBI Vaccines
机构投资者参与VBI疫苗
A number of hedge funds and other institutional investors have recently bought and sold shares of VBIV. State Street Corp grew its holdings in VBI Vaccines by 31.1% in the first quarter. State Street Corp now owns 16,216,811 shares of the biopharmaceutical company's stock worth $26,920,000 after purchasing an additional 3,844,698 shares during the period. Millennium Management LLC grew its holdings in VBI Vaccines by 211.7% in the second quarter. Millennium Management LLC now owns 1,780,752 shares of the biopharmaceutical company's stock worth $1,440,000 after purchasing an additional 1,209,393 shares during the period. Renaissance Technologies LLC grew its holdings in shares of VBI Vaccines by 358.7% during the second quarter. Renaissance Technologies LLC now owns 789,500 shares of the biopharmaceutical company's stock valued at $638,000 after buying an additional 617,400 shares during the last quarter. Frontier Wealth Management LLC grew its holdings in shares of VBI Vaccines by 1,571.7% during the first quarter. Frontier Wealth Management LLC now owns 601,800 shares of the biopharmaceutical company's stock valued at $951,000 after buying an additional 565,800 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of VBI Vaccines by 88.9% during the first quarter. Bank of America Corp DE now owns 809,425 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 380,839 shares during the last quarter. Hedge funds and other institutional investors own 39.96% of the company's stock.
一些对冲基金和其他机构投资者最近买卖了VBIV的股票。道富集团第一季度持有的VBI疫苗增加了31.1%。道富集团目前持有这家生物制药公司16,216,811股股票，价值26,920,000美元，在此期间又购买了3,844,698股。千禧管理有限责任公司在第二季度增持了VBI疫苗211.7%。Millennium Management LLC现在拥有这家生物制药公司1,780,752股股票，价值1，44万美元，在此期间又购买了1,209,393股。复兴科技有限责任公司在第二季度增持了358.7%的VBI疫苗股票。复兴科技有限责任公司现在拥有这家生物制药公司78.95万股票，价值63.8万美元，在上个季度又购买了61.74万股票。FronTier Wealth Management LLC在第一季度增持了VBI疫苗股票1,571.7%。FronTier Wealth Management LLC现在拥有601,800股这家生物制药公司的股票，价值951,000美元，此前在上个季度又购买了565,800股。最后，美国银行DE在第一季度增持了VBI疫苗公司的股票88.9%。美国银行DE目前持有809,425股这家生物制药公司的股票，价值1,343,000美元，此前在上一季度又购买了380,839股。对冲基金和其他机构投资者持有该公司39.96%的股票。
About VBI Vaccines
关于VBI疫苗
(Get Rating)
(获取评级)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
VBI疫苗公司是一家生物制药公司，开发和销售用于治疗传染病和免疫肿瘤学的疫苗。该公司提供一种预防性乙肝疫苗Sci-B-Vac。它还参与VBI-2601(BRII-179)的开发，VBI-2601(BRII-179)是治疗慢性乙肝感染的免疫治疗候选药物。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on VBI Vaccines (VBIV)
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- This Is A Memorable Time To Buy Into Micron Technology
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- Declining Profits Challenge the CarMax Value Proposition
- 免费获取StockNews.com关于VBI疫苗的研究报告(VBIV)
- 电动汽车电池制造商Freyr将在全球大举扩张
- MarketBeat：回顾一周9/26-9/30
- 这是买入美光科技的难忘时刻
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何？
- 利润下降对CarMax价值主张的挑战
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到VBI疫苗的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对VBI疫苗和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧